Abstract
Former economic analyses have shown that universal mass vaccination of infants against varicella using a one-dose schedule is cost-saving in Germany. In July 2006, an MMRV combination vaccine has been approved in Germany which shall be given in a two-dose schedule. We re-analysed our former analysis with the EVITA model in order to prove whether our former conclusion that universal mass vaccination against varicella is cost-saving is still valid when using a two-dose schedule vaccine. Indeed we found that universal mass vaccination of infants against varicella with a two-dose vaccine is cost-saving from societal as well as from health care perspective.
MeSH terms
-
Adolescent
-
Chickenpox Vaccine / administration & dosage*
-
Chickenpox Vaccine / economics*
-
Child
-
Child, Preschool
-
Cost Savings
-
Germany
-
Humans
-
Immunization Programs / economics
-
Immunization Programs / statistics & numerical data
-
Immunization Schedule
-
Infant
-
Mass Vaccination / economics*
-
Mass Vaccination / statistics & numerical data
-
Measles-Mumps-Rubella Vaccine / administration & dosage*
-
Measles-Mumps-Rubella Vaccine / economics*
-
Models, Economic
-
Models, Statistical
-
Sensitivity and Specificity
-
Vaccines, Combined / administration & dosage
-
Vaccines, Combined / economics
Substances
-
Chickenpox Vaccine
-
Measles-Mumps-Rubella Vaccine
-
Vaccines, Combined
-
measles, mumps, rubella, varicella vaccine